Mispro Expands Boston Footprint with Contract Vivarium Facility at Southline
'With each new facility, we're investing in more than square footage—we're expanding access to a smarter, de-risked model for in vivo research,' said Yohan Tessier, President & COO of Mispro.
Located within Southline's 700,000+ square foot life sciences campus, the new facility expands Mispro's support for early- and growth-stage biotechs across Greater Boston. As the first company to introduce the contract vivarium (CV) model to the metro area, Mispro remains a critical partner to venture-backed startups and established programs seeking speed, control, and reproducible data in preclinical development.
'With each new facility, we're investing in more than square footage—we're expanding access to a smarter, de-risked model for in vivo research,' said Yohan Tessier, President & COO of Mispro. 'The contract vivarium option reduces infrastructure burdens while keeping scientific control where it belongs, which is with the biotech teams who are driving discovery forward.'
Southline is also home to Portal Innovations, a leading early-stage venture firm and life sciences incubator. The proximity of Mispro's vivarium services offers immediate operational advantages to Portal's member companies and other tenants.
'Having Mispro onsite brings in vivo capacity directly into the heart of our ecosystem, giving early-stage teams immediate access to high-quality preclinical capabilities,' said Portal's Executive Director in Boston, Tatiana Yglesias. 'This streamlined access supports lean operations, accelerates timelines, protects IP, and meaningfully de-risks development—key advantages in today's fast-moving and capital-conscious funding environment.'
To date in 2025, 75% of biotech M&A activity has involved companies conducting studies in Mispro facilities. The company currently supports 45 Boston-area biotechs and continues to grow alongside the region's expanding R&D ecosystem.
'This expansion reflects our commitment to enabling science that moves—not just forward, but faster,' added Tessier.
Mispro's Southline contract vivarium facility is set to open in October. Learn more about the location here.
ABOUT MISPRO
Mispro is a leading contract vivarium organization providing biomedical researchers with turnkey, full-service vivarium facilities to conduct preclinical in vivo studies. With locations in metro Boston/Cambridge, New York, Raleigh-Durham (RTP), Philadelphia, South San Francisco, Palo Alto, San Carlos, and Montreal, Mispro enables innovation by offering a flexible, cost-effective alternative to outsourcing early-stage studies or internalizing an in-house vivarium. For more information, visit www.mispro.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Covid is rising. New vaccines may not be ready until mid-September.
Coronavirus infections are climbing again, marking another summer wave as children go back to school. But this uptick arrives with an added layer of uncertainty because it's unclear when and which Americans can receive updated vaccines this fall. Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. Daniel R. Kuritzkes, chief of the division of infectious diseases at Brigham and Women's Hospital in Boston, said the current rise looks similar to seasonal bumps in previous years and is not driving a surge in severe illness. This is the new rhythm of covid waves. Many people are getting sick - some feeling lousy - especially after returning from vacation and conferences. Most probably won't even know it's covid because the symptoms can be indistinguishable from a cold or other respiratory bug. Yet hospitals are no longer flooded with patients because immune systems are much better trained to fight the virus five years after it arrived. But Kuritzkes and other medical and public health experts worry that delays and confusion surrounding the vaccines will limit access for those who need them the most: Adults ages 65 and older and people who have chronic conditions, weakened immune systems or are pregnant. The federal committee that would recommend the updated coronavirus vaccine is not expected to meet until at least mid-September, according to industry employees and Centers for Disease Control and Prevention officials who spoke on the condition of anonymity to share sensitive information. By that point, the summer covid wave could be over, but Americans could still get a boost of immunity ahead of an expected winter wave. Here's what to know about the latest with covid and how to protect yourself: - - - What does the data show? Several metrics tracked by the CDC show a midsummer uptick of coronavirus underway in the United States. Viral levels in wastewater started rising in late June and are considered high in the West, South and Midwest and headed that direction in the Northeast, according to Marlene Wolfe, principal investigator and co-program director of WastewaterSCAN, a private initiative that tracks municipal sewage data. The levels of virus are roughly one-third of the levels recorded a year ago, when the country was experiencing an unusually large summer covid wave. Emergency room data suggests infections are disproportionately affecting children. As of Aug. 7, coronavirus diagnoses accounted for 2.18 percent of emergency room visits among children up to age 11, the largest jump of any age group. Still, some experts caution that numbers are still very small. Aaron Milstone, a pediatric infectious-disease specialist at Johns Hopkins University School of Medicine, said most children now have some level of hybrid immunity from prior infection and vaccination. But vaccines still play a key role in giving a child's body a robust immune response, he said. 'Parents get frustrated that they get their kids the vaccine and they still contract it, but the biggest point is that they didn't die or get severe illness,' said Milstone. 'It's like wearing a seat belt. It doesn't prevent an accident, but it decreases the likelihood of dying from one.' - - - What are the latest variants? Coronavirus is always evolving to become more transmissible or adept at overcoming the frontline immune defenses that stop infections. The current predominant variant is XFG, according to CDC wastewater tracking. XFG is an offshoot of the JN.1 subvariant of omicron that became dominant in the winter of 2023-2024. The Food and Drug Administration has advised vaccine manufacturers to update their formulas to target the JN.1 lineage, specifically using the LP.8.1 strain that was dominant in the spring and is closely related to XFG. The latest variants do not appear to cause worse symptoms or have significant differences compared with its predecessors, according to Scott Roberts, an assistant professor of infectious diseases at Yale School of Medicine. - - - What's the latest with vaccines? For the coming fall season, the FDA has not yet approved an updated coronavirus vaccine. In recent years, the agency has typically signed off on an updated version by late August or early September in order for pharmacies and doctors' offices to place orders. But the agency is expected to narrow its approval for the vaccine to those 65 and older, as well as others considered at high risk for severe disease. The new approach marks a significant shift from past years when the shots have been broadly available, including to children and generally healthy adults. Once the FDA gives the greenlight, the CDC's Advisory Committee on Immunization Practices decides who should get the shots. Most insurers must pay for ACIP-recommended vaccines. Most of the newly appointed members of that committee have been critical of U.S. coronavirus vaccine policy. It's unclear whether Americans who are not considered high risk could still pay out-of-pocket to get a coronavirus vaccine off-label. That depends on the willingness of - and legal restrictions on - health care providers who would administer shots. Most Americans have at least one condition that puts them at higher risk of severe illness from covid. Physical inactivity, asthma, obesity, smoking and mood disorders are among the widespread risk factors highlighted under the new FDA framework for coronavirus vaccine approval. AHIP, the major insurance lobby, has said its members are committed to maintaining coverage of vaccines for the upcoming respiratory virus season. The FDA may not sign off on Pfizer's updated coronavirus vaccine for children between the ages of six months and 4, the company said in a statement, adding the change has nothing to do with the safety and efficacy of the shot. However, the agency recently granted full approval to Moderna's shot for young kids at risk of severe disease. The CDC stopped offering specific coronavirus vaccine guidance to pregnant women. The American College of Obstetricians and Gynecologists has strongly criticized that move, noting research has shown the virus can be dangerous for expecting mothers and cause birth complications. - - - How can I protect myself and others? Public health experts say the best way to protect yourself from covid is to stay up-to-date on vaccines. The 2024-2025 vaccine formula is still available. But it might be harder to find because some doctors and pharmacies may have decided not to restock their supplies while they wait for a new version to arrive. The CDC recommends two doses of the vaccine for people who are 65 and older or are immunocompromised. Jessica Justman, an infectious disease specialist at Columbia University, said if someone in those groups had not yet received their second dose, they should go ahead and get it now, especially if they anticipate increased exposure such as attending a large indoor gathering. The primary purpose of vaccination is to reduce the risk of severe disease, hospitalization and death. For those wanting to avoid infections completely, experts advise wearing surgical or KN95/N95 masks, avoiding crowded indoor settings and ventilating rooms. For those who get infected, the CDC guidance to resume normal activities is to wait until your symptoms are improving and you have been fever-free for 24 hours without using fever-reducing medication. Then you should take precautions for an additional five days, such as social distancing and masking. - - - Rachel Roubein and Lena H. Sun contributed to this report Related Content Ukraine scrambles to roll back Russian eastern advance as summit takes place Her dogs kept dying, and she got cancer. Then they tested her water. D.C.'s homeless begin to see the effects of Trump's crackdown Solve the daily Crossword
San Francisco Chronicle
5 hours ago
- San Francisco Chronicle
Fatal explosion at U.S. Steel's plant raises questions about its future, despite heavy investment
HARRISBURG, Pa. (AP) — The fatal explosion last week at U.S. Steel's Pittsburgh-area coal-processing plant has revived debate about its future just as the iconic American company was emerging from a long period of uncertainty. The fortunes of steelmaking in the U.S. — along with profits, share prices and steel prices — have been buoyed by years of friendly administrations in Washington that slapped tariffs on foreign imports and bolstered the industry's anti-competitive trade cases against China. Most recently, President Donald Trump's administration postponed new hazardous air pollution requirements for the nation's roughly dozen coke plants, like Clairton, and he approved U.S. Steel's nearly $15 billion acquisition by Japanese steelmaker Nippon Steel. Nippon Steel's promised infusion of cash has brought vows that steelmaking will continue in the Mon Valley, a river valley south of Pittsburgh long synonymous with steelmaking. 'We're investing money here. And we wouldn't have done the deal with Nippon Steel if we weren't absolutely sure that we were going to have an enduring future here in the Mon Valley," David Burritt, U.S. Steel's CEO, told a news conference the day after the explosion. 'You can count on this facility to be around for a long, long time.' Will the explosion change anything? The explosion killed two workers and hospitalized 10 with a blast so powerful that it took hours to find two missing workers beneath charred wreckage and rubble. The cause is under investigation. The plant is considered the largest coking operation in North America and, along with a blast furnace and finishing mill up the Monongahela River, is one of a handful of integrated steelmaking operations left in the U.S. The explosion now could test Nippon Steel's resolve in propping up the nearly 110-year-old Clairton plant, or at least force it to spend more than it had anticipated. Nippon Steel didn't respond to a question as to whether the explosion will change its approach to the plant. Rather, a spokesperson for the company said its 'commitment to the Mon Valley remains strong' and that it sent 'technical experts to work with the local teams in the Clairton Plant, and to provide our full support.' Meanwhile, Burritt said he had talked to top Nippon Steel officials after the explosion and that 'this facility and the Mon Valley are here to stay.' U.S. Steel officials maintain that safety is their top priority and that they spend $100 million a year on environmental compliance at Clairton alone. However, repairing Clairton could be expensive, an investigation into the explosion could turn up more problems, and an official from the United Steelworkers union said it's a constant struggle to get U.S. Steel to invest in its plants. Besides that, production at the facility could be affected for some time. The plant has six batteries of ovens and two — where the explosion occurred — were damaged. Two others are on a reduced production schedule because of the explosion. There is no timeline to get the damaged batteries running again, U.S. Steel said. Accidents are nothing new at Clairton Accidents are nothing new at Clairton, which heats coal to high temperatures to make coke, a key component in steelmaking, and produces combustible gases as byproducts. An explosion in February injured two workers. Even as Nippon Steel was closing the deal in June, a breakdown at the plant dealt three days of a rotten egg odor into the air around it from elevated hydrogen sulfide emissions, the environmental group GASP reported. The Breathe Project, a public health organization, said U.S. Steel has been forced to pay $57 million in fines and settlements since Jan. 1, 2020, for problems at the Clairton plant. A lawsuit over a Christmas Eve fire at the Clairton plant in 2018 that saturated the area's air for weeks with sulfur dioxide produced a withering assessment of conditions there. An engineer for the environmental groups that sued wrote that he 'found no indication that U.S. Steel has an effective, comprehensive maintenance program for the Clairton plant.' The Clairton plant, he wrote, is "inherently dangerous because of the combination of its deficient maintenance and its defective design." U.S. Steel settled, agreeing to spend millions on upgrades. Matthew Mehalik, executive director of the Breathe Project, said U.S. Steel has shown more willingness to spend money on fines, lobbying the government and buying back shares to reward shareholders than making its plants safe. Will Clairton be modernized? It's not clear whether Nippon Steel will change Clairton. Central to Trump's approval of the acquisition was Nippon Steel's promises to invest $11 billion into U.S. Steel's aging plants and to give the federal government a say in decisions involving domestic steel production, including plant closings. But much of the $2.2 billion that Nippon Steel has earmarked for the Mon Valley plants is expected to go toward upgrading the finishing mill, or building a new one. For years before the acquisition, U.S. Steel had signaled that the Mon Valley was on the chopping block. That left workers there uncertain whether they'd have jobs in a couple years and whispering that U.S. Steel couldn't fill openings because nobody believed the jobs would exist much longer. Relics of steelmaking's past In many ways, U.S. Steel's Mon Valley plants are relics of steelmaking's past. In the early 1970s, U.S. steel production led the world and was at an all-time high, thanks to 62 coke plants that fed 141 blast furnaces. Nobody in the U.S. has built a blast furnace since then, as foreign competition devastated the American steel industry and coal fell out of favor. Now, China is dominant in steel and heavily invested in coal-based steelmaking. In the U.S., there are barely a dozen coke plants and blast furnaces left, as the country's steelmaking has shifted to cheaper electric arc furnaces that use electricity, not coal. Blast furnaces won't entirely go away, analysts say, since they produce metals that are preferred by automakers, appliance makers and oil and gas exploration firms. Still, Christopher Briem, an economist at the University of Pittsburgh's Center for Social and Urban Research, questioned whether the Clairton plant really will survive much longer, given its age and condition. It could be particularly vulnerable if the economy slides into recession or the fundamentals of the American steel market shift, he said. 'I'm not quite sure it's all set in stone as people believe,' Briem said. 'If the market does not bode well for U.S. Steel, for American steel, is Nippon Steel really going to keep these things?'
Boston Globe
20 hours ago
- Boston Globe
Hawaiian Airlines to cancel only direct flight to Boston
'Despite our team's best efforts, soft post-pandemic travel demand from Asia combined with various market challenges have persisted in Seoul, as well as in Fukuoka and Boston,' Hawaiian Airlines CEO Joe Sprague said. The airline began service to Boston in 2019 and currently operates four direct, non-stop flights between Logan International Airport and Honolulu's Daniel K. Inouye International Airport each week. Advertisement Logan International Airport did not immediately respond to a request for comment. Hawaiian Airlines was the only airline that offered direct flights between Logan International Airport in Boston and Daniel K. Inouye International Airport in Honolulu, according to the 'We remain committed to continuing to provide robust Hawaiian Airlines service between Asia and Hawai'i through our nonstop Japan flights, and via one-stop connections to and from Incheon and beyond with our global partner airlines,' Sprague said. The suspension is set to go into effect Nov. 19, when all direct flights between Boston and Honolulu will cease operation. After the suspension, Boston-based travelers will have to arrange for connecting flights on their route to Honolulu and the state of Hawai'i. Advertisement 'Between Honolulu and Boston, guests can connect daily on Alaska Airlines' flights via Seattle, Portland, San Francisco and San Diego,' Hawaiian Airlines said in the statement. Travelers who booked Hawaiian Airlines flights between Honolulu and Boston after the Nov. 19 suspension will be reaccommodated with another flight to their location or receive a refund, the airline said in the statement announcing the suspension. The planes that were used to fly between Honolulu and Logan International will redirect their courses to support high-demand flight paths, the airline said. In the statement, Hawaiian Airlines said that the aircraft will be redeployed to offer an increased number of flights between Honolulu and Sydney, Australia, Papeete, Tahiti, Los Angeles, and Seattle. 'These adjustments will ensure we are meeting strong demand for travel to Hawaiʻi – both internationally and domestically – while providing all our guests access to more destinations,' Sprague said. Hawaiian Airlines and Alaska Airlines The deal was intended to offer more flights between the 138 destinations the airlines accommodate and maintain Honolulu as a travel hub, the Katie Cressman can be reached at
